

Next-generation anti-TIGIT antibody (7043H1E) with enhanced Fc function

HanAll Biopharma



ONCOLOGY	Candidate
Product Type	Immunoglobulin Product [Fully human mAb, Fc-enhanced]
Indication	1st Indication: Refractory solid tumors 2nd Indication: Pancreatic cancer, Prostate cancer, Breast cancer, etc.
Target	TIGIT (T cell immunoreceptor with Ig and ITIM domains)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Binds to TIGIT expressed on T or NK cells to interrupt interactions of TIGIT and its ligands, CD155(or CD112) • Augment immune responses via enhancing Fc-FcγR co-engagement • Depletes TIGIT+ regulatory T cells by ADCC activity of NK cells
Competitiveness	<ul style="list-style-type: none"> • Increased in vitro/in vivo efficacy compared to competitors' Fc-wt anti-TIGIT antibodies • Converting tumor microenvironment from immune-suppressive to immune-supportive condition by depletion of regulatory T cells
Development Stage	Candidate
Route of Administration	Parenteral-intravenous